title: Tumour-infiltrating CD68+ and CD57+ cells predict patient outcome in stage II-III colorectal cancer.
abstract: BACKGROUND
  The aim of our study was to evaluate the prognostic role of immunological microenvironnement in stage II-III CRC patients.
  
  
  METHODS
  We constructed a tissue microarray from 196 consecutive patients with stage II-III CRC and compared CD3, CD4, CD8, CD57, CD68, CXCL9/MIG, CXCL13, and PPARγ immunoreactivity in tumour samples and their matched non-tumour tissue. We assessed their association with relapse-free survival (RFS; primary endpoint) and overall survival (OS) in multivariate Cox models.
  
  
  RESULTS
  Low densities of CD57+ and CD68+ tumour-infiltrating cells (TIC) independently predicted worse outcomes. A prognostic score combining CD57 (+, > vs -, ≤2 cells per spot) and CD68 (+, >0 vs -, =0 cells per spot) TIC density discriminated CRC patients at low (CD68+/CD57+), intermediate (CD68+/CD57-), or high (CD68-/CD57-) risk, with hazard ratios for the intermediate-risk and high-risk groups of 2.7 (95% confidence interval (CI): 1.3-5.8) and 9.0 (3.2-25.4) for RFS, and 2.5 (1.2-5.1) and 10.6 (3.8-29.2) for OS, respectively, as compared with the low-risk group. Corresponding 5-year survival rates (95% CI) in the low-, moderate- and high-risk groups were 84% (71-91), 65% (54-74), and 12% (2-47), respectively, for RFS, and 91% (80-96), 76% (66-84), and 25% (7-59), respectively, for OS.
  
  
  CONCLUSIONS
  Tumour CD57+ and CD68+ TIC density assessment independently predicts survival in patients with stage II-III CRC. If validated, our score based on a quick, inexpensive, and well-established method such as point counting on diagnostic tissue sections could be used routinely as a prognostic tool in CRC patients.
authors.affiliation: Centre of clinical investigation in biotherapy CIC-BT 507, Institut Gustave Roussy, Villejuif, France.
authors.forename: N
authors.initials: N
authors.lastname: Chaput
authors.forename: M
authors.initials: M
authors.lastname: Svrcek
authors.forename: A
authors.initials: A
authors.lastname: Aupérin
authors.forename: C
authors.initials: C
authors.lastname: Locher
authors.forename: F
authors.initials: F
authors.lastname: Drusch
authors.forename: D
authors.initials: D
authors.lastname: Malka
authors.forename: J
authors.initials: J
authors.lastname: Taïeb
authors.forename: D
authors.initials: D
authors.lastname: Goéré
authors.forename: M
authors.initials: M
authors.lastname: Ducreux
authors.forename: V
authors.initials: V
authors.lastname: Boige
mesh_terms: D000230:Adenocarcinoma / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015703:Antigens, CD / Q000276:immunology*; D015214:Antigens, Differentiation, Myelomonocytic / Q000276:immunology*; D015415:Biomarkers; D017252:CD3 Complex / Q000276:immunology; D015704:CD4 Antigens / Q000276:immunology; D018959:CD57 Antigens / Q000276:immunology*; D016827:CD8 Antigens / Q000276:immunology; D002452:Cell Count; D054382:Chemokine CXCL13 / Q000276:immunology; D054370:Chemokine CXCL9 / Q000276:immunology; D015179:Colorectal Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D008264:Macrophages / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D047495:PPAR gamma / Q000276:immunology; D011379:Prognosis; D016016:Proportional Hazards Models; D000097382:CD68 Molecule
chemical_list: D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D015415:Biomarkers; D017252:CD3 Complex; D015704:CD4 Antigens; D018959:CD57 Antigens; D016827:CD8 Antigens; D054382:Chemokine CXCL13; D054370:Chemokine CXCL9; D047495:PPAR gamma; C067980:CD68 antigen, human; D000097382:CD68 Molecule; C110663:CXCL13 protein, human; C080810:CXCL9 protein, human